At a glance
ClinicalIndex Comparison RecordN/ACompleted· 110 enrolled
Drug / intervention
Afatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Real-World Outcomes Associated With Afatinib (Gilotrif) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions
In Brief
An observational study evaluating Afatinib and other systemic therapy for Non-squamous, Non-Small Cell Lung Cancer. Completed, enrolled 110 participants across 1 site.
Detailed Summary
Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-squamous, Non-Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedFeb 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedFeb 11, 2021
Enrollment StartOct 15, 2020
Primary CompletionDec 20, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.4 years ago
Interventions
Afatinibdrug
Afatinib
other systemic therapydrug
other systemic therapy